fulvestrant

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Selective estrogen receptor degrader

Related drugs:

ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant + anastrozole Sensitive: A2 - Guideline fulvestrant + anastrozole Sensitive : A2	fulvestrant + anastrozole Sensitive: A2 - Guideline fulvestrant + anastrozole Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	fulvestrant + letrozole Sensitive: A2 - Guideline fulvestrant + letrozole Sensitive : A2	fulvestrant + letrozole Sensitive: A2 - Guideline fulvestrant + letrozole Sensitive : A2
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
ESR1 wild-type + HR positive	HER2 Positive Breast Cancer	ESR1 wild-type + HR positive	HER2 Positive Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
ESR1 mutation + HR positive	HER2 Negative Breast Cancer	ESR1 mutation + HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B
ER mutation	Hormone Receptor Positive Breast Cancer	ER mutation	Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B
TP53 mutation	Breast Cancer	TP53 mutation	Breast Cancer	fulvestrant Resistant: B - Late Trials fulvestrant Resistant : B	fulvestrant Resistant: B - Late Trials fulvestrant Resistant : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: C1 - Off-label fulvestrant Sensitive : C1	fulvestrant Sensitive: C1 - Off-label fulvestrant Sensitive : C1
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	fulvestrant Sensitive: C1 - Off-label fulvestrant Sensitive : C1	fulvestrant Sensitive: C1 - Off-label fulvestrant Sensitive : C1
ER mutation	Breast Cancer	ER mutation	Breast Cancer	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2
ER positive + PGR positive	HER2 Negative Breast Cancer	ER positive + PGR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2
ER D538G	Breast Cancer	ER D538G	Breast Cancer	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	Immunotherapy + fulvestrant Sensitive: C2 – Inclusion Criteria Immunotherapy + fulvestrant Sensitive : C2	Immunotherapy + fulvestrant Sensitive: C2 – Inclusion Criteria Immunotherapy + fulvestrant Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PI3K inhibitor + fulvestrant Sensitive: C2 – Inclusion Criteria PI3K inhibitor + fulvestrant Sensitive : C2	PI3K inhibitor + fulvestrant Sensitive: C2 – Inclusion Criteria PI3K inhibitor + fulvestrant Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive: C2 – Inclusion Criteria CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive : C2	CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive: C2 – Inclusion Criteria CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive : C2
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: C3 – Early Trials fulvestrant Sensitive : C3	fulvestrant Sensitive: C3 – Early Trials fulvestrant Sensitive : C3
CDK6 overexpression	Estrogen Receptor Positive Breast Cancer	CDK6 overexpression	Estrogen Receptor Positive Breast Cancer	fulvestrant Resistant: C3 – Early Trials fulvestrant Resistant : C3	fulvestrant Resistant: C3 – Early Trials fulvestrant Resistant : C3
TK1 elevation	Hormone Receptor Positive Breast Cancer	TK1 elevation	Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials fulvestrant + anastrozole Sensitive : C3	fulvestrant + anastrozole Sensitive: C3 – Early Trials fulvestrant + anastrozole Sensitive : C3
BRCA2 mutation	Hormone Receptor Positive Breast Cancer	BRCA2 mutation	Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Resistant: C3 – Early Trials fulvestrant + anastrozole Resistant : C3	fulvestrant + anastrozole Resistant: C3 – Early Trials fulvestrant + anastrozole Resistant : C3
BRCA1 mutation	Hormone Receptor Positive Breast Cancer	BRCA1 mutation	Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Resistant: C3 – Early Trials fulvestrant + anastrozole Resistant : C3	fulvestrant + anastrozole Resistant: C3 – Early Trials fulvestrant + anastrozole Resistant : C3
PIK3CA mutation	Hormone Receptor Positive Breast Cancer	PIK3CA mutation	Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials fulvestrant + anastrozole Sensitive : C3	fulvestrant + anastrozole Sensitive: C3 – Early Trials fulvestrant + anastrozole Sensitive : C3

fulvestrant

Associations
(57)

Associations
(57)

fulvestrant

Associations(57)

Associations(57)

Associations
(57)

Associations
(57)